Cyclophosphamide/fludarabine/ibrutinibHepatitis-B reactivation and acquired-resistance leading to no effect: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1923卷 / 1期

关键词：

D O I：

10.1007/s40278-022-23029-y

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：166 / 166

相关论文

共 50 条

[21] TerbinafineDrug resistance leading to no effect : case report
Reactions Weekly, 2024, 2017 (1) : 466 - 466
[22] BendamustineHepatitis B reactivation (first report) leading to fatal liver failure: case report
Reactions Weekly, 2011, 1353 (1) : 8 - 8
[23] Multiple drugsCytomegalovirus infection reactivation, acquired resistance and lack of efficacy: case report
Reactions Weekly, 2023, 1959 (1) : 434 - 434
[24] InfliximabLamivudine resistance and reactivation of hepatitis B infection: case report
Reactions Weekly, 2008, 1184 (1) : 23 - 23
[25] LamivudineDevelopment of resistance, resulting in hepatitis B reactivation: case report
Reactions Weekly, 2013, 1447 (1) : 26 - 26
[26] MethotrexateHepatitis B virus reactivation leading to fatal liver failure: case report
Reactions Weekly, 2008, 1192 (1) : 25 - 25
[27] Cyclophosphamide/fludarabine/rituximabReactivation of hepatitis B virus infection and anicteric acute hepatitis: case report
Reactions Weekly, 2016, 1626 (1) : 61 - 61
[28] Multiple drugsLack of efficacy, and acquired resistance leading to treatment failure: case report
Reactions Weekly, 2022, 1933 (1) : 306 - 306
[29] AntineoplasticsLack of drug effect and acquired resistance: case report
Reactions Weekly, 2022, 1888 (1) : 51 - 51
[30] Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report
H. Ng
L. Lim
Annals of Hematology, 2001, 80 : 549 - 552

← 1 2 3 4 5 →